Tumor necrosis factor-α gene polymorphism correlates with cardiovascular disease in patients with end-stage renal disease

Molecular Diagnosis and Therapy

Volumn 11, Issue 4, 2007, Pages 257-263

  Buraczynska, Monika ^a   Mierzicki, Piotr ^a   Buraczynska, Kinga ^a   Dragan, Michał ^a   Ksiazek, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 34548433956     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256247     Document Type: Article

References (40)

1. Bergström J, Lindholm B. Malnutrition, cardiac disease, and mortality: an integrated point of view. Am J Kid Dis 1998; 32 (5): 834-41
2. Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65 (6): 2380-9
3. Stenvinkel P, Pecoits-Filho R, Lindholm B, for the DialGene Consortium. Gene polymorphism-association studies in dialysis: the nutrition-inflammation axis. Semin Dialysis 2005; 18 (4): 322-30
4. Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, therosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int 2004; 8: 118-29
5. Stenvinkel P, Kettler M, Johnson RJ, et al. IL-10, IL-6 and TNF-α: central factors in the altered cytokine network of uremia. The good, the bad and the ugly. Kidney Int 2005; 67 (4): 1216-33
6. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334 (26): 1717-25
7. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340 (2): 115-26
8. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997; 94 (7): 3195-9
9. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-α promoter polymorphism affects transcription. Mol Immunol 1997; 34 (5): 391-9
10. Hajeer AH, Hutchinson IV. TNF-α gene polymorphism: clinical and biological Implications. Microsc Res Tech 2000; 50 (3): 216-28
11. Lee SC, Pu YB, Thomas GN, et al. Tumor necrosis factor alpha gene G -308A polymorphism in the metabolic syndrome. Metabolism 2000; 49 (8): 1021-4
12. Wang Y, Ng MC, So WY, et al. Association between tumor necrosis factor-alpha G -308A polymorphism and risk of nephropathy in obese Chinese type 2 diabetic patients. Nephrol Dial Transplant 2005; 20 (12): 2733-8
13. Knight JC, Kwiatkowski D. Inherited variability of tumor necrosis factor production and susceptibility to infectious disease. Proc Assoc Am Physicians 1999; 111: 290-8
14. Simmonds MJ, Heward JM, Howson JM, et al. A systematic approach to the assessment of known TNF-alpha polymorphisms in Graves' disease. Genes Immun 2204; 5: 267-73
15. Reich K, Mössner R, König IR, et al. Promoter polymorphisms of the genes encoding tumor necrosis factor-α and interleukin-1β are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 2002; 118: 155-63
16. Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis: relationship with activation markers of T cells, B-cells and monocytes. J Immunol 1995; 154 (2): 882-92
17. Espinoza M, Aguilera A, Auxiladora Bajo M, et al. Tumor necrosis factor alpha as a uremic toxin: correlation with neuropathy, left ventricular hypertrophy, anemia and hypertriglyceridemia in peritoneal dialysis patients. Adv Perit Dial 1995; 15: 82-6
18. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int 2000; 57 Suppl. 75: S7-14
19. Shu K-H, Lee S-H, Cheng C-H, et al. Impact of interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphism on IgA nephropathy. Kidney Int 2000; 58 (2): 783-9
20. Lee S-H, Lee TW, Ihm C-G, et al. Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation. Nephrology 2005; 10 Suppl.: S32-6
21. Hermann S-M, Ricard S, Nicaud V, et al. Polymorphisms of the tumor necrosis factor-α gene, coronary heart disease and obesity. Eur J Clin Invest 1998; 28 (1): 59-66
22. Allen RA, Lee EM, Roberts DH, et al. Polymorphisms in the TNF-α and TNF receptor genes in patients with coronary artery disease. Eur J Clin Invest 2001; 31 (10): 843-51
23. Olmer M, Renucci JE, Planells R, et al. Preliminary evidence for a role of apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk. Nephrol Dial Transplant 1997; 12 (4): 691-3
24. Kimura H, Gejyo F, Suzuki S, et al. A C677T mutation in the 5,10-methylene-tetrahydrofolate reductase gene modifies serum cysteine in dialysis patients. Am J Kidney Dis 2000; 36 (5): 925-33
25. Wong TY, Poon P, Szeto CC, et al. Association of plasminogen activator inhibitor-1 4G/4G and type 2 diabetic nephropathy in Chinese patients. Kidney Int 2000; 57 (2): 632-8
26. Pernod G, Bosson J-L, Golshayan D, et al. Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort. Kidney Int 2006; 69 (8): 1424-30
27. Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney Int 2005; 68 (4): 1413-8
28. Balakrishnan VS, Guo D, Rao M, et al. Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int 2004; 65 (4): 1449-60
29. Spriewald BM, Witzke O, Wassmuth R, et al. Distinct tumor necrosis factor α, interferon γ, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis. Ann Rheum Dis 2005; 64 (3): 457-61
30. Manchanda PK, Kumar A, Kaul A, et al. Correlation between a gene polymorphism of tumor necrosis factor alpha (G/A) and end stage renal disease: a pilot study from North India. Clin Chim Acta 2006; 370 (1-2): 152-7
31. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998; 54 (1): 236-44
32. Bernard V, Pillois S, Dubus I, et al. The -308 G/A tumor necrosis-α gene dimorphism: a risk factor for unstable angina. Clin Chem Lab Med 2003; 41: 511-4
33. Locatelli F, Covic A, Chazot C, et al. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant 2004; 19 (5): 1058-68
34. Losito A, Kalidas K, Santoni S, et al. Association of interleukin-6 -174 G/C polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003; 64 (2): 616-22
35. Shiau M-Y, Wu C-Y, Huang C-N, et al. TNF-α polymorphisms and type 2 diabetes mellitus in Taiwanese patients. Tissue Antigens 2003; 61: 393-7
36. Stuber F, Udalova A, Book M, et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and it is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1996; 46: 32-41
37. Keso T, Perola M, Lippala P, et al. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis 2001; 154 (3): 691-7
38. Gallagher G, Eskdale J, Oh H, et al. Polymorphisms in the TNF gene cluster and MHC serotypes in the West of Scotland. Immunogenetics 1997; 45: 188-94
39. Jacob CO, Fronek Z, Lewis GD, et al. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor-α: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A 1990; 87 (3): 1223-37
40. Lakka H-M, Lakka TA, Rankinen T, et al. The TNF-α G -308A polymorphism is associated with C-reactive protein levels: the HERITAGE Family Study. Vasc Pharmacol 2006; 44: 377-83